ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Wegener’s granulomatosis and polyangiitis"

  • Abstract Number: 1664 • 2019 ACR/ARP Annual Meeting

    Reducing the Number of Rituximab Infusions at Onset of Maintenance Therapy for ANCA-associated Vasculitides: Results of a Post Hoc Analysis from a Randomized–controlled Trial

    Pierre Charles1, Agnes Dechartres 2, Benjamin Terrier 3, Pascal Cohen 3, Stanislas Faguer 4, Antoine Huart 4, Mohamed Hamidou 5, Christian Agard 5, Bernard Bonnotte 6, Maxime Samson 7, Alexandre Karras 8, Noémie Jourde-Chiche 9, François Lifermann 10, Pierre Gobert 11, Catherine Hanrotel-Saliou 12, Pascal Godmer 13, Nicolas Martin-Silva 14, Grégory Pugnet 15, Marie Matignon 16, Olivier Aumaitre 17, Jean-François Viallard 18, François Maurier 19, Nadine Meaux Ruault 20, Sophie Rivière 21, Jean Sibilia 22, Xavier Puéchal for the French Vasculitis Study Group 3, Luc Mouthon 3 and Loic Guillevin 3, 1Institut Mutualiste Montsouris, Paris, France, 2APHP, Paris, France, 3National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, 4CHU Toulouse, Toulouse, France, 5CHU Nantes, Nantes, France, 6Service de Médecine Interne et Immunologie Clinique, CHU Dijon Bourgogne, Hôpital François Mitterrand, Dijon ; Université Bourgogne-Franche Comté, INSERM, EFS BFC, UMR1098, F-21000 Dijon, Dijon, France, 7CHU Dijon, Dijon, France, 8Paris HEGP, Paris, France, 9APHM, Marseille, Marseille, France, 10CH Dax, Dax, France, 11CH Avignon, Avignon, France, 12CHU Brest, Brest, France, 13CH Bretagne-Atlantique, Vannes, France, 14CHU Caen, Caen, France, 15CHU de Toulouse, Hôpital Purpan, Service de Médecine Interne, Toulouse, France, 16APHP, Créteil, France, 17CHU Clermont Ferrand, Clermont Ferrand, France, 18CHU Bordeaux, Bordeaux, France, 19Service de Médecine Interne, Hôpital Belle Isle, Metz, Metz, France, 20CHU Besançon, Besançon, France, 21CHU Montpellier, Montpellier, France, 22CHU Strasbourg, Strasbourg, France

    Background/Purpose: Rituximab (RTX) superiority over azathioprine to maintain ANCA-associated vasculitis (AAV) remission was demonstrated.The MAINRITSAN2 trial was designed to compare an individually tailored RTX-infusion schedule…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology